Comment on "A small-molecule antivirulence agent for treating Clostridium difficile infection"

Greg L Beilhartz; John Tam; Zhifen Zhang; Roman A Melnyk

doi:10.1126/scitranslmed.aad8926

Comment on "A small-molecule antivirulence agent for treating Clostridium difficile infection"

Sci Transl Med. 2016 Dec 21;8(370):370tc2. doi: 10.1126/scitranslmed.aad8926.

Authors

Greg L Beilhartz¹, John Tam¹, Zhifen Zhang^{1

2}, Roman A Melnyk^{3

2}

Affiliations

¹ Molecular Structure & Function, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada.
² Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
³ Molecular Structure & Function, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada. roman.melnyk@sickkids.ca.

PMID: 28003550
DOI: 10.1126/scitranslmed.aad8926

Abstract

New insights into the mechanism of action of ebselen, a small-molecule antivirulence agent that reduces disease pathology in a mouse model of Clostridium difficile infection, suggest a different molecular target may be responsible for its efficacy.

Publication types

Comment

MeSH terms

Animals
Anti-Bacterial Agents
Clostridioides difficile*
Clostridium Infections*
Mice

Substances

Anti-Bacterial Agents